Journal article
Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data
Abstract
Abstract
Authors
Pechlivanoglou P; Luu L; Li Q; Gibson PJ; Athale UH; Bassal M; Breakey VR; Patel S; Pole J; Sutradhar R
Journal
Blood, Vol. 138, No. Supplement 1,
Publisher
American Society of Hematology
Publication Date
November 5, 2021
DOI
10.1182/blood-2021-154193
ISSN
0006-4971